News
ACONW
0.0324
-0.61%
-0.0002
Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate
Benzinga · 5h ago
Insider Move: Aclarion Director Makes Bold New Share Purchase
TipRanks · 1d ago
Aclarion director Scott Breidbart acquires 5,664 shares worth $18,012.48
PUBT · 1d ago
Aclarion director David K. Neal acquires 2,500 common shares worth $7,750
PUBT · 1d ago
Top Executive Makes Bold Insider Move at Aclarion, Inc.
TipRanks · 2d ago
Weekly Report: what happened at ACON last week (0504-0508)?
Weekly Report · 2d ago
Aclarion director William Wesemann acquires 1,562 common shares for $5,154.6
PUBT · 5d ago
Aclarion Adds Lanman Spinal Neurosurgery As Clinical Site In CLARITY Trial
Benzinga · 6d ago
ACLARION INC - EXPECTS PUBLIC DISCLOSURE OF EARLY INTERIM CLARITY TRIAL RESULTS IN Q4 2026
Reuters · 6d ago
ACLARION ANNOUNCES ADDITION OF FIRST PRIVATE PRACTICE SITE IN LOS ANGELES INTO CLARITY TRIAL TO FURTHER ACCELERATE ENROLLMENT
Reuters · 6d ago
Aclarion grants new Western US commercial director option for 17,000 shares at $3.2
PUBT · 05/06 10:04
Press Release: Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Dow Jones · 05/06 10:00
Aclarion Signs Agreement With Weill Cornell For Use Of Nociscan To Treat Lumbar Disc Disease
NASDAQ · 05/05 14:58
Aclarion enters second commercial agreement with Weill Cornell Medicine
TipRanks · 05/05 11:37
Aclarion Establishes Second Commercial Agreement With Weill Cornell Medicine; Deal Brings Nociscan To Weill Cornell Medicine And Och Spine At Newyork-Presbyterian/Weill Cornell Medical Center
Benzinga · 05/05 10:11
BRIEF-Aclarion Announces Second Commercial Agreement With Weill Cornell Medicine
Reuters · 05/05 10:08
Aclarion signs second commercial agreement with Weill Cornell Medicine for Nociscan trial
PUBT · 05/05 10:05
Weekly Report: what happened at ACON last week (0427-0501)?
Weekly Report · 05/04 10:00
Aclarion, Inc. reports Q1 results
Seeking Alpha · 05/01 13:31
Aclarion announces $2.5 million share buyback program
PUBT · 04/30 10:10
More
Webull provides a variety of real-time ACONW stock news. You can receive the latest news about ACLARION INC through multiple platforms. This information may help you make smarter investment decisions.
About ACONW
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.